BMY logo Bristol-Myers Squibb Company +
Bristol-Myers Squibb Company
+

Bristol-Myers Squibb Company (BMY) Business News

Track Bristol-Myers Squibb Company in real time with a live news feed covering Bristol-Myers Squibb Company stock news, official press releases, company announcements, and an archive of historical Bristol-Myers Squibb Company news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

Business Wire

6:59 AM | Monday | Jul 13, 2026

news photo
Loading...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma.

Read full article redirect
6:59 AM | Monday | Jul 13, 2026

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma.

Read full article arrow
News Thumbnail
8:00 AM | Friday | Jul 10, 2026

Start Investing At 60 And Retire On Dividends Forever

Seeking Alpha

Retiring on dividends remains achievable for late starters by building a high-yield, quality portfolio targeting a 6% yield with safe, growing payouts. Dividend-focused strategies mitigate sequence of returns risk, enabling investors to live off income rather than depleting principal during market downturns. Examples like Enbridge Inc. (ENB), Omega Healthcare Investors, Inc. (OHI), and Bristol-Myers Squibb Company (BMY) illustrate our buy low, sell high, and get paid to wait principles, delivering strong returns and dividend growth.

Read full article arrow
News Thumbnail
10:45 AM | Tuesday | Jul 7, 2026

3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)

The Motley Fool

AbbVie is hitting its stride now that it has transitioned past Humira's patent expiration. Medtronic is a steady dividend payer with some intriguing upside in robotics-assisted surgery.

Read full article arrow
News Thumbnail
4:44 AM | Monday | Jul 6, 2026

Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know.

The Motley Fool

Bristol Myers Squibb is generating more than enough earnings to cover its dividend right now. However, the company faces a daunting patent cliff.

Read full article arrow
News Thumbnail
9:25 AM | Friday | Jul 3, 2026

Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes

Seeking Alpha

BMY's growth portfolio now comprises 54.1% of revenues and delivered +9% YoY growth in FQ1'26 against the legacy portfolio's slower erosion, supporting further upside to the currently conservative FY2026 guidance. Strategic partnerships with Jiangsu Hengrui, accretive M&As, and strong uptake of Opdivo Qvantig underpin the company's multi-pronged portfolio renewal efforts, despite the near-term IPRD noise. BMY's intermediate-term top/bottom-line growth prospects are likely to underwhelm due to LOE risks from Eliquis/Opdivo, albeit with secure dividend payouts at 39.2% of free cash flow.

Read full article arrow
News Thumbnail
10:01 AM | Wednesday | Jul 1, 2026

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Zacks Investment Research

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read full article arrow
News Thumbnail
7:30 AM | Wednesday | Jul 1, 2026

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool

Bristol Myers Squibb focuses on specialized medicines in oncology and immunology, and shares sport a low valuation. Johnson & Johnson offers a diversified business model spanning innovative medicines and medical technology.

Read full article arrow
News Thumbnail
10:41 AM | Tuesday | Jun 30, 2026

Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

Zacks Investment Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read full article arrow
News Thumbnail
7:45 AM | Tuesday | Jun 30, 2026

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Fool - Investing News

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

Read full article arrow
News Thumbnail
10:51 AM | Monday | Jun 29, 2026

66 With $1.3 Million. Here Are 3 Hidden Gems to Target

247 Wallst

At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into each dividend to see which ones a 66-year-old can actually rely on.
Bristol Myers Squibb:... 66 With $1.3 Million.
Here Are 3 Hidden Gems to Target

Read full article arrow
News Thumbnail